Bio-Techne Corp Stock Price, News & Analysis (NASDAQ:TECH)

$129.22 0.61 (0.47 %)
(As of 11/20/2017 10:22 AM ET)
Previous Close$128.61
Today's Range$127.31 - $129.63
52-Week Range$95.68 - $132.57
Volume115,900 shs
Average Volume166,956 shs
Market Capitalization$4.84086 billion
P/E Ratio37.24
Dividend Yield1.00%
Beta0.74

About Bio-Techne Corp (NASDAQ:TECH)

Bio-Techne Corp logoBio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through three segments: Biotechnology, Clinical Controls and Protein Platforms. The Biotechnology segment develops, manufactures and sells biotechnology research and diagnostic products, such as cytokines, growth factors, immunoassays, antibodies and related reagents, across the world. The Clinical Controls segment develops and manufactures controls, calibrators, immunoassays and other reagents for the global clinical market. The Protein Platforms segment develops and commercializes systems and consumables for protein analysis. It markets immunoassays on different testing platforms, including microtiter-plate based kits sold under the trade name Quantikine, and immunoassays based on planar spotted surfaces and microfluidic-based multiplex immunoassays on automated testing platform.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Life Sciences Tools & Services
  • Sector: Medical
  • Symbol: NASDAQ:TECH
  • CUSIP: 87837710
  • Web: www.techne-corp.com
Debt:
  • Debt-to-Equity Ratio: 0.35%
  • Current Ratio: 2.87%
  • Quick Ratio: 2.25%
Price-To-Earnings:
  • Trailing P/E Ratio: 37.24
  • Forward P/E Ratio: 34.37
  • P/E Growth: 3.22
Sales & Book Value:
  • Annual Sales: $563 million
  • Price / Sales: 8.60
  • Cash Flow: $5.05 per share
  • Price / Cash: 25.61
  • Book Value: $25.44 per share
  • Price / Book: 5.08
Dividend:
  • Annual Dividend: $1.28
  • Dividend Yield: 1.0%
Profitability:
  • Trailing EPS: $1.93
  • Net Income: $76.08 million
  • Net Margins: 12.54%
  • Return on Equity: 14.11%
  • Return on Assets: 8.52%
Misc:
  • Employees: 1,800
  • Outstanding Shares: 37,460,000
 

Frequently Asked Questions for Bio-Techne Corp (NASDAQ:TECH)

What is Bio-Techne Corp's stock symbol?

Bio-Techne Corp trades on the NASDAQ under the ticker symbol "TECH."

How often does Bio-Techne Corp pay dividends? What is the dividend yield for Bio-Techne Corp?

Bio-Techne Corp announced a quarterly dividend on Tuesday, October 31st. Shareholders of record on Friday, November 10th will be paid a dividend of $0.32 per share on Friday, November 24th. This represents a $1.28 dividend on an annualized basis and a yield of 0.99%. The ex-dividend date is Thursday, November 9th. View Bio-Techne Corp's Dividend History.

How were Bio-Techne Corp's earnings last quarter?

Bio-Techne Corp (NASDAQ:TECH) posted its quarterly earnings data on Tuesday, October, 31st. The biotechnology company reported $0.90 EPS for the quarter, beating the Zacks' consensus estimate of $0.82 by $0.08. The biotechnology company had revenue of $144.61 million for the quarter, compared to analyst estimates of $142.37 million. Bio-Techne Corp had a return on equity of 14.11% and a net margin of 12.54%. The firm's revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.84 earnings per share. View Bio-Techne Corp's Earnings History.

When will Bio-Techne Corp make its next earnings announcement?

Bio-Techne Corp is scheduled to release their next quarterly earnings announcement on Monday, February, 5th 2018. View Earnings Estimates for Bio-Techne Corp.

Where is Bio-Techne Corp's stock going? Where will Bio-Techne Corp's stock price be in 2017?

4 brokerages have issued 1 year target prices for Bio-Techne Corp's stock. Their forecasts range from $115.00 to $145.00. On average, they expect Bio-Techne Corp's stock price to reach $130.00 in the next year. View Analyst Ratings for Bio-Techne Corp.

Who are some of Bio-Techne Corp's key competitors?

Who are Bio-Techne Corp's key executives?

Bio-Techne Corp's management team includes the folowing people:

  • Robert V. Baumgartner CPA, Independent Chairman of the Board (Age 60)
  • Charles R. Kummeth, President, Chief Executive Officer, Director (Age 56)
  • Roger C. Lucas Ph.D., Independent Vice Chairman of the Board (Age 73)
  • James T. Hippel, Chief Financial Officer, Senior Vice President (Age 45)
  • Brenda S. Furlow J.D., Senior Vice President, General Counsel, Secretary (Age 58)
  • David Eansor, Senior Vice President - Biotechnology (Age 54)
  • Robert Gavin, Senior Vice President-Protein Platforms (Age 48)
  • Kevin S. Gould, Senior Vice President-Clinical Controls (Age 52)
  • J. Fernando Bazan Ph.D., Chief Technology Officer (Age 56)
  • Joseph D. Keegan Ph.D., Director (Age 64)

Who owns Bio-Techne Corp stock?

Bio-Techne Corp's stock is owned by many different of institutional and retail investors. Top institutional investors include Atlanta Capital Management Co. L L C (5.20%), Neuberger Berman Group LLC (4.76%), Bamco Inc. NY (4.06%), Janus Henderson Group PLC (3.00%), Jackson Square Partners LLC (2.30%) and Royce & Associates LP (1.76%). Company insiders that own Bio-Techne Corp stock include Charles A Dinarello, John L Higgins, Karen A Holbrook, Kevin S Gould, Robert V Baumgartner and Roger C Lucas. View Institutional Ownership Trends for Bio-Techne Corp.

Who sold Bio-Techne Corp stock? Who is selling Bio-Techne Corp stock?

Bio-Techne Corp's stock was sold by a variety of institutional investors in the last quarter, including American Century Companies Inc., Segall Bryant & Hamill LLC, Royce & Associates LP, Janus Henderson Group PLC, Neuberger Berman Group LLC, Kornitzer Capital Management Inc. KS, Mackenzie Financial Corp and Riverbridge Partners LLC. Company insiders that have sold Bio-Techne Corp company stock in the last year include Charles A Dinarello, Karen A Holbrook, Robert V Baumgartner and Roger C Lucas. View Insider Buying and Selling for Bio-Techne Corp.

Who bought Bio-Techne Corp stock? Who is buying Bio-Techne Corp stock?

Bio-Techne Corp's stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, State of Tennessee Treasury Department, Assenagon Asset Management S.A., Foundry Partners LLC, Jackson Square Partners LLC, Tygh Capital Management Inc., Public Employees Retirement Association of Colorado and Sivik Global Healthcare LLC. View Insider Buying and Selling for Bio-Techne Corp.

How do I buy Bio-Techne Corp stock?

Shares of Bio-Techne Corp can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Techne Corp's stock price today?

One share of Bio-Techne Corp stock can currently be purchased for approximately $129.22.

How big of a company is Bio-Techne Corp?

Bio-Techne Corp has a market capitalization of $4.84086 billion and generates $563 million in revenue each year. The biotechnology company earns $76.08 million in net income (profit) each year or $1.93 on an earnings per share basis. Bio-Techne Corp employs 1,800 workers across the globe.

How can I contact Bio-Techne Corp?

Bio-Techne Corp's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854.


MarketBeat Community Rating for Bio-Techne Corp (NASDAQ TECH)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  122 (Vote Outperform)
Underperform Votes:  175 (Vote Underperform)
Total Votes:  297
MarketBeat's community ratings are surveys of what our community members think about Bio-Techne Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Bio-Techne Corp (NASDAQ:TECH)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 2 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $130.00 (0.60% upside)

Consensus Price Target History for Bio-Techne Corp (NASDAQ:TECH)

Price Target History for Bio-Techne Corp (NASDAQ:TECH)

Analysts' Ratings History for Bio-Techne Corp (NASDAQ:TECH)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/31/2017Deutsche Bank AGSet Price TargetBuy$145.00N/AView Rating Details
10/24/2017Citigroup Inc.Reiterated RatingBuy$125.00 -> $115.00N/AView Rating Details
7/13/2017Wells Fargo & CompanyInitiated CoverageMarket Perform -> Market PerformLowView Rating Details
3/27/2017Janney Montgomery ScottDowngradeBuy -> NeutralHighView Rating Details
11/10/2016Leerink SwannInitiated CoverageOutperform$122.00N/AView Rating Details
8/18/2016Robert W. BairdBoost Price TargetOutperform$115.00 -> $116.00N/AView Rating Details
(Data available from 11/20/2015 forward)

Earnings

Earnings History and Estimates Chart for Bio-Techne Corp (NASDAQ:TECH)

Earnings by Quarter for Bio-Techne Corp (NASDAQ:TECH)

Earnings History by Quarter for Bio-Techne Corp (NASDAQ TECH)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/5/2018N/AView Earnings Details
10/31/2017Q1 2018$0.82$0.90$142.37 million$144.61 millionViewN/AView Earnings Details
8/8/2017Q4 2017$0.99$1.09$150.25 million$156.60 millionViewListenView Earnings Details
5/2/2017Q3 2017$0.93$0.97$142.83 million$144.04 millionViewListenView Earnings Details
2/7/2017Q217$0.85$0.81$134.74 million$131.80 millionViewListenView Earnings Details
10/31/2016Q117$0.79$0.84$127.47 million$130.60 millionViewListenView Earnings Details
8/17/2016Q416$0.96$0.92$129.23 million$134.80 millionViewListenView Earnings Details
5/3/2016Q316$0.89$1.01$122.65 million$131.00 millionViewN/AView Earnings Details
2/2/2016Q216$0.82$0.88$118.59 million$120.90 millionViewN/AView Earnings Details
10/28/2015Q1$0.85$0.79$116.91 million$12.40 millionViewListenView Earnings Details
8/6/2015Q415$0.86$0.87$116.85 million$117.70 millionViewN/AView Earnings Details
5/5/2015Q315$0.91$0.86$119.30 million$114.20 millionViewN/AView Earnings Details
2/3/2015Q215$0.86$0.89$112.73 million$111.90 millionViewN/AView Earnings Details
10/28/2014Q115$0.87$0.85$108.65 million$108.50 millionViewN/AView Earnings Details
8/11/2014Q414$0.85$0.88$91.80 million$92.50 millionViewN/AView Earnings Details
4/28/2014Q314$0.89$0.94$92.50 million$95.60 millionViewN/AView Earnings Details
2/4/2014Q214$0.80$0.75$84.79 million$84.00 millionViewN/AView Earnings Details
10/29/2013Q114$0.80$0.83$82.36 million$85.70 millionViewN/AView Earnings Details
8/6/2013Q4 2013$0.83$0.82$79.71 million$79.50 millionViewN/AView Earnings Details
4/30/2013Q3 2013$0.90$0.88$84.00 million$81.00 millionViewN/AView Earnings Details
2/5/2013Q2 2013$0.77$0.74$76.40 million$75.10 millionViewN/AView Earnings Details
10/23/2012$0.79$0.75ViewN/AView Earnings Details
7/31/2012$0.85$0.80ViewN/AView Earnings Details
5/1/2012$0.89$0.90ViewN/AView Earnings Details
1/31/2012$0.79$0.76ViewN/AView Earnings Details
10/25/2011$0.84$0.81ViewN/AView Earnings Details
8/2/2011$0.76$0.76ViewN/AView Earnings Details
5/3/2011$0.80$0.84ViewN/AView Earnings Details
2/1/2011$0.68$0.71ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bio-Techne Corp (NASDAQ:TECH)
2017 EPS Consensus Estimate: $3.49
2018 EPS Consensus Estimate: $3.77
2019 EPS Consensus Estimate: $4.03
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173$0.76$0.81$0.78
Q2 20173$0.81$0.85$0.83
Q3 20173$0.90$0.96$0.93
Q4 20173$0.93$0.98$0.95
Q1 20181$0.88$0.88$0.88
Q2 20182$0.84$0.89$0.87
Q3 20182$0.96$0.98$0.97
Q4 20182$1.02$1.09$1.06
Q1 20191$0.89$0.89$0.89
Q2 20191$0.92$0.92$0.92
Q3 20191$1.04$1.04$1.04
Q4 20191$1.18$1.18$1.18
(Data provided by Zacks Investment Research)

Dividends

Current Dividend Information for Bio-Techne Corp (NASDAQ:TECH)

Next Dividend:11/24/2017
Annual Dividend:$1.28
Dividend Yield:0.99%
Payout Ratio:66.32% (Trailing 12 Months of Earnings)
34.04% (Based on This Year's Estimates)
30.84% (Based on Next Year's Estimates)
Dividend Payments by Quarter for Bio-Techne Corp (NASDAQ:TECH)

Dividend History by Quarter for Bio-Techne Corp (NASDAQ TECH)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/31/2017Quarterly$0.321%11/9/201711/10/201711/24/2017
8/9/2017Quarterly$0.321.1%8/16/20178/18/20179/1/2017
5/2/2017quarterly$0.321.15%5/17/20175/19/20176/2/2017
2/7/2017quarterly$0.321.27%2/15/20172/17/20173/3/2017
11/1/2016Quarterly$0.3211/9/201611/14/201611/28/2016
8/17/2016quarterly$0.328/25/20168/29/20169/12/2016
5/3/2016quarterly$0.321.27%5/11/20165/13/20165/27/2016
2/2/2016quarterly$0.321.48%2/10/20162/12/20162/26/2016
10/29/2015quarterly$0.321.45%11/10/201511/13/201511/27/2015
8/6/2015quarterly$0.321.18%8/13/20158/17/20158/28/2015
5/5/2015quarterly$0.321.31%5/11/20155/15/20155/29/2015
2/3/2015quarterly$0.321.4%2/11/20152/13/20152/27/2015
10/30/2014quarterly$0.321.41%11/6/201411/10/201411/24/2014
8/11/2014quarterly$0.311.31%8/19/20148/21/20148/29/2014
4/28/2014quarterly$0.311.37%5/7/20145/9/20145/23/2014
2/4/2014quarterly$0.311.48%2/12/20142/14/20142/28/2014
10/31/2013quarterly$0.311.4%11/7/201311/12/201311/25/2013
8/6/2013quarterly$0.301.62%8/14/20138/16/20138/31/2013
4/30/2013quarterly$0.301.86%5/8/20135/10/20135/24/2013
2/5/2013quarterly$0.301.74%2/13/20132/15/20133/1/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for Bio-Techne Corp (NASDAQ TECH)

Insider Ownership Percentage: 3.40%
Institutional Ownership Percentage: 97.18%
Insider Trades by Quarter for Bio-Techne Corp (NASDAQ:TECH)
Institutional Ownership by Quarter for Bio-Techne Corp (NASDAQ:TECH)

Insider Trades by Quarter for Bio-Techne Corp (NASDAQ TECH)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/1/2017Robert V BaumgartnerDirectorSell5,000$130.18$650,900.00View SEC Filing  
10/10/2017Roger C LucasDirectorSell100$121.96$12,196.00View SEC Filing  
9/8/2017Roger C LucasDirectorSell100$120.94$12,094.00View SEC Filing  
9/6/2017Karen A HolbrookDirectorSell1,059$121.73$128,912.07View SEC Filing  
8/10/2017Roger C LucasDirectorSell100$114.30$11,430.00View SEC Filing  
7/10/2017Roger C LucasDirectorSell100$116.86$11,686.00View SEC Filing  
6/9/2017Roger C LucasDirectorSell100$113.62$11,362.00View SEC Filing  
5/31/2017Charles A DinarelloDirectorSell5,000$111.37$556,850.00View SEC Filing  
5/25/2017Karen A HolbrookDirectorSell5,000$111.15$555,750.00View SEC Filing  
5/10/2017Roger C LucasDirectorSell100$110.59$11,059.00View SEC Filing  
4/10/2017Roger C LucasDirectorSell100$101.15$10,115.00View SEC Filing  
1/10/2017Roger C LucasDirectorSell100$103.57$10,357.00View SEC Filing  
11/29/2016Karen A HolbrookDirectorSell1,000$106.73$106,730.00View SEC Filing  
11/16/2016Roger C LucasDirectorSell100$105.75$10,575.00View SEC Filing  
9/21/2016Roger C LucasDirectorSell100$108.91$10,891.00View SEC Filing  
9/8/2016John L HigginsDirectorSell1,700$109.83$186,711.00View SEC Filing  
9/8/2016Kevin S. GouldSVPSell524$110.50$57,902.00View SEC Filing  
9/2/2016Robert V BaumgartnerDirectorSell6,467$107.17$693,068.39View SEC Filing  
8/24/2016Robert V BaumgartnerDirectorSell3,533$107.10$378,384.30View SEC Filing  
8/17/2016Roger C. LucasDirectorSell100$113.70$11,370.00View SEC Filing  
7/20/2016Roger C LucasDirectorSell100$111.03$11,103.00View SEC Filing  
6/15/2016Roger C LucasDirectorSell100$112.15$11,215.00View SEC Filing  
5/18/2016Roger C LucasDirectorSell100$102.53$10,253.00View SEC Filing  
5/9/2016Charles A DinarelloDirectorSell5,000$101.91$509,550.00View SEC Filing  
5/6/2016Roger C LucasDirectorSell500$100.24$50,120.00View SEC Filing  
4/20/2016Roger C LucasDirectorSell100$92.40$9,240.00View SEC Filing  
3/16/2016Roger C LucasDirectorSell100$92.90$9,290.00View SEC Filing  
2/5/2016Roger C. LucasDirectorSell5,000$83.68$418,400.00View SEC Filing  
8/13/2015Roger C LucasDirectorSell5,000$106.01$530,050.00View SEC Filing  
6/8/2015Randolph C SteerDirectorSell1,000$99.39$99,390.00View SEC Filing  
2/19/2015Howard V OconnellDirectorSell5,000$95.78$478,900.00View SEC Filing  
12/10/2014Karen A HolbrookDirectorSell1,000$92.40$92,400.00View SEC Filing  
12/9/2014Kevin J ReaganVPSell3,591$89.35$320,855.85View SEC Filing  
12/8/2014Charles A DinarelloDirectorSell3,000$90.44$271,320.00View SEC Filing  
8/14/2014Karen A HolbrookDirectorSell5,000$95.54$477,700.00View SEC Filing  
5/7/2014Howard OconnellDirectorSell5,000$91.00$455,000.00View SEC Filing  
3/4/2014Karen HolbrookDirectorSell5,000$89.83$449,150.00View SEC Filing  
2/27/2014Randolph SteerDirectorSell5,000$88.78$443,900.00View SEC Filing  
11/13/2013Randolph SteerDirectorSell15,000$86.20$1,293,000.00View SEC Filing  
11/8/2013Robert BaumgartnerDirectorSell10,000$87.00$870,000.00View SEC Filing  
11/4/2013Roger C LucasDirectorSell10,000$87.64$876,400.00View SEC Filing  
5/6/2013Howard V OconnellDirectorBuy2,361$65.00$153,465.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Bio-Techne Corp (NASDAQ TECH)

Source:
DateHeadline
Bio-Techne Offers Updated Novus Panel Builder, Facilitating Multicolor Flow Cytometry Panel DesignBio-Techne Offers Updated Novus Panel Builder, Facilitating Multicolor Flow Cytometry Panel Design
www.prnewswire.com - November 20 at 8:11 AM
Bio-Techne Corp. :TECH-US: Earnings Analysis: Q1, 2018 By the Numbers : November 16, 2017Bio-Techne Corp. :TECH-US: Earnings Analysis: Q1, 2018 By the Numbers : November 16, 2017
finance.yahoo.com - November 18 at 9:13 AM
ETFs with exposure to Bio-Techne Corp. : November 17, 2017ETFs with exposure to Bio-Techne Corp. : November 17, 2017
finance.yahoo.com - November 18 at 9:13 AM
Bio-Techne Awards 40,000 USD Research Grant to Innovative Cancer ResearcherBio-Techne Awards 40,000 USD Research Grant to Innovative Cancer Researcher
finance.yahoo.com - November 14 at 3:49 PM
 Brokerages Expect Bio-Techne Corp (TECH) Will Post Quarterly Sales of $145.90 Million Brokerages Expect Bio-Techne Corp (TECH) Will Post Quarterly Sales of $145.90 Million
www.americanbankingnews.com - November 10 at 9:58 AM
Robust Earnings Momentum Metrics Drive Upgrade of Bio-Techne (TECH) to BuyRobust Earnings Momentum Metrics Drive Upgrade of Bio-Techne (TECH) to Buy
investorplace.com - November 9 at 3:38 PM
Featured Company News - Japanese Patent Office Issued New Patent to Alexion Pharmas Soliris; Extending Patent Protection into 2027Featured Company News - Japanese Patent Office Issued New Patent to Alexion Pharma's Soliris; Extending Patent Protection into 2027
finance.yahoo.com - November 9 at 2:31 PM
Women In Bio Announces that Alpna Seth Joins Bio-Techne’s Board of DirectorsWomen In Bio Announces that Alpna Seth Joins Bio-Techne’s Board of Directors
finance.yahoo.com - November 7 at 11:49 AM
Women In Bio Announces that Alpna Seth Joins Bio-Technes Board of DirectorsWomen In Bio Announces that Alpna Seth Joins Bio-Techne's Board of Directors
feeds.benzinga.com - November 7 at 10:07 AM
Q2 2018 EPS Estimates for Bio-Techne Corp Raised by William Blair (TECH)Q2 2018 EPS Estimates for Bio-Techne Corp Raised by William Blair (TECH)
www.americanbankingnews.com - November 6 at 11:52 AM
Bio-Techne Corp (TECH) Given Average Rating of "Buy" by AnalystsBio-Techne Corp (TECH) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - November 5 at 7:38 AM
Bio-Techne Corp (TECH) Rating Increased to Buy at Zacks Investment ResearchBio-Techne Corp (TECH) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - November 4 at 8:23 AM
Insider Selling: Bio-Techne Corp (TECH) Director Sells 5,000 Shares of StockInsider Selling: Bio-Techne Corp (TECH) Director Sells 5,000 Shares of Stock
www.americanbankingnews.com - November 3 at 5:42 PM
Bio-Techne Shows Market Leadership With Jump To 81 RS RatingBio-Techne Shows Market Leadership With Jump To 81 RS Rating
finance.yahoo.com - November 2 at 9:40 AM
Bio-Techne Corp (TECH) Plans Quarterly Dividend of $0.32Bio-Techne Corp (TECH) Plans Quarterly Dividend of $0.32
www.americanbankingnews.com - November 1 at 10:32 AM
Edited Transcript of TECH earnings conference call or presentation 31-Oct-17 1:00pm GMTEdited Transcript of TECH earnings conference call or presentation 31-Oct-17 1:00pm GMT
finance.yahoo.com - November 1 at 1:54 AM
BRIEF-Bio-Techne releases Q1 adjusted earnings per share $0.90BRIEF-Bio-Techne releases Q1 adjusted earnings per share $0.90
www.reuters.com - October 31 at 3:51 PM
Bio-Techne (TECH) Q1 2018 Results - Earnings Call TranscriptBio-Techne (TECH) Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - October 31 at 3:51 PM
Deutsche Bank AG Analysts Give Bio-Techne Corp (TECH) a $145.00 Price TargetDeutsche Bank AG Analysts Give Bio-Techne Corp (TECH) a $145.00 Price Target
www.americanbankingnews.com - October 31 at 3:25 PM
Is a Surprise Coming for Bio-Techne (TECH) This Earnings Season?Is a Surprise Coming for Bio-Techne (TECH) This Earnings Season?
finance.yahoo.com - October 31 at 10:30 AM
ETFs with exposure to Bio-Techne Corp. : October 30, 2017ETFs with exposure to Bio-Techne Corp. : October 30, 2017
finance.yahoo.com - October 31 at 10:30 AM
Bio-Techne to Host Earnings CallBio-Techne to Host Earnings Call
finance.yahoo.com - October 31 at 10:30 AM
Bio-Techne Releases First Quarter Fiscal 2018 ResultsBio-Techne Releases First Quarter Fiscal 2018 Results
finance.yahoo.com - October 31 at 10:30 AM
Bio-Techne Corp (TECH) Issues Quarterly  Earnings ResultsBio-Techne Corp (TECH) Issues Quarterly Earnings Results
www.americanbankingnews.com - October 31 at 8:56 AM
Bio-Techne To Present At The Stephens Fall Investment ConferenceBio-Techne To Present At The Stephens Fall Investment Conference
finance.yahoo.com - October 27 at 4:11 PM
Bio-Techne Adds Two New Directors to Its BoardBio-Techne Adds Two New Directors to Its Board
finance.yahoo.com - October 27 at 6:41 AM
Bio-Techne Corp (TECH) Set to Announce Earnings on TuesdayBio-Techne Corp (TECH) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - October 24 at 9:38 AM
Bio-Techne Corp (TECH) Expected to Post Earnings of $0.89 Per ShareBio-Techne Corp (TECH) Expected to Post Earnings of $0.89 Per Share
www.americanbankingnews.com - October 19 at 11:35 AM
Comparing Global Blood Therapeutics (GBT) and BIO-TECHNE Corp (TECH)Comparing Global Blood Therapeutics (GBT) and BIO-TECHNE Corp (TECH)
www.americanbankingnews.com - October 17 at 4:30 PM
Bio-Techne Reaches Analyst Target PriceBio-Techne Reaches Analyst Target Price
www.nasdaq.com - October 14 at 8:33 AM
Roger C. Lucas Sells 100 Shares of Bio-Techne Corp (TECH) StockRoger C. Lucas Sells 100 Shares of Bio-Techne Corp (TECH) Stock
www.americanbankingnews.com - October 12 at 7:50 PM
Bio-Techne Corp (TECH) Raised to "Buy" at Zacks Investment ResearchBio-Techne Corp (TECH) Raised to "Buy" at Zacks Investment Research
www.americanbankingnews.com - October 11 at 1:32 PM
Bio-Techne Corp (TECH) Given Average Rating of "Buy" by BrokeragesBio-Techne Corp (TECH) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - October 11 at 8:49 AM
ETFs with exposure to Bio-Techne Corp. : October 10, 2017ETFs with exposure to Bio-Techne Corp. : October 10, 2017
finance.yahoo.com - October 11 at 8:26 AM
Bio-Techne To Host Conference Call On October 31, 2017 To Announce First Quarter 2018 Financial ResultsBio-Techne To Host Conference Call On October 31, 2017 To Announce First Quarter 2018 Financial Results
finance.yahoo.com - October 11 at 8:26 AM
Bio-Techne Corp. :TECH-US: Earnings Analysis: Q4, 2017 By the Numbers : October 9, 2017Bio-Techne Corp. :TECH-US: Earnings Analysis: Q4, 2017 By the Numbers : October 9, 2017
finance.yahoo.com - October 10 at 7:26 AM
Joint Consortia Framework Awards Contract to Bio-Techne as Supplier of Research AntibodiesJoint Consortia Framework Awards Contract to Bio-Techne as Supplier of Research Antibodies
finance.yahoo.com - October 6 at 11:08 AM
Bio-Techne Corp (TECH) & Its Competitors Head-To-Head ComparisonBio-Techne Corp (TECH) & Its Competitors Head-To-Head Comparison
www.americanbankingnews.com - October 4 at 8:36 AM
Bio-Techne's New Simple Plex Cartridge Boosts Protein SegmentBio-Techne's New Simple Plex Cartridge Boosts Protein Segment
finance.yahoo.com - October 3 at 1:26 PM
Bio-Techne Shows Rising Relative Strength; Still Shy Of Key BenchmarkBio-Techne Shows Rising Relative Strength; Still Shy Of Key Benchmark
finance.yahoo.com - October 3 at 1:26 PM
$142.75 Million in Sales Expected for Bio-Techne Corp (TECH) This Quarter$142.75 Million in Sales Expected for Bio-Techne Corp (TECH) This Quarter
www.americanbankingnews.com - October 2 at 5:18 AM
 Analysts Expect Bio-Techne Corp (TECH) Will Announce Earnings of $0.89 Per Share Analysts Expect Bio-Techne Corp (TECH) Will Announce Earnings of $0.89 Per Share
www.americanbankingnews.com - September 30 at 2:20 PM
Berkeley accelerator adds money to the mixBerkeley accelerator adds money to the mix
www.bizjournals.com - September 29 at 9:38 AM
Bio-Techne Unveils a New Multi-Analyte Cartridge Format for the Ella™ Immunoassay Platform, Improving Sample ThroughputBio-Techne Unveils a New Multi-Analyte Cartridge Format for the Ella™ Immunoassay Platform, Improving Sample Throughput
finance.yahoo.com - September 20 at 9:50 AM
Bio-Techne Corp (TECH) Given Consensus Rating of "Buy" by AnalystsBio-Techne Corp (TECH) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - September 16 at 8:34 AM
ETFs with exposure to Bio-Techne Corp. : September 14, 2017ETFs with exposure to Bio-Techne Corp. : September 14, 2017
finance.yahoo.com - September 14 at 11:05 AM
Bio-Techne CEO Charles Kummeths compensation jumps to $9.1MBio-Techne CEO Charles Kummeth's compensation jumps to $9.1M
www.bizjournals.com - September 13 at 10:00 AM
Bio-Techne Introduces a New Luminex Multi-analyte Assay KitBio-Techne Introduces a New Luminex Multi-analyte Assay Kit
finance.yahoo.com - September 13 at 10:00 AM
Insider Selling: Bio-Techne Corp (TECH) Director Sells 100 Shares of StockInsider Selling: Bio-Techne Corp (TECH) Director Sells 100 Shares of Stock
www.americanbankingnews.com - September 12 at 8:24 PM
Bio-Techne Corp. :TECH-US: Earnings Analysis: 2017 By the Numbers : September 11, 2017Bio-Techne Corp. :TECH-US: Earnings Analysis: 2017 By the Numbers : September 11, 2017
finance.yahoo.com - September 12 at 10:47 AM

Social Media

Financials

Chart

Bio-Techne Corp (NASDAQ TECH) Chart for Monday, November, 20, 2017
Loading chart…

This page was last updated on 11/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.